Takeda and Innovent's Claudin 18.2 ADC Wins Phase 3 in Gastric Cancer
- Phase 3 G-HOPE-001, presented as a late-breaker at ESMO, met its dual primary endpoints of overall and progression-free survival versus physician's-choice chemotherapy in previously treated CLDN18.2-positive gastric cancer.
- The trial enrolled about 460 patients in China and Japan; Fierce reports median overall survival of roughly ten months for the ADC.
- Takeda plans a Japanese filing and says it will pursue global trials in gastric and pancreatic cancer.
💡 Points Based on public reports
This validates Takeda's roughly $1.2B Innovent partnership and gives it a real foothold in a claudin 18.2 field that AstraZeneca is also chasing. The open question is exportability: an all China-and-Japan dataset will face questions from FDA, so the global trials Takeda promises are where the asset's value is actually decided.
ESMO: Takeda's $1.2B bet on Innovent 'absolutely' pays off with details of ADC's phase 3 win ↗